Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 11

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 8
Chunk 11
---

			374

			374

			$
			246.96

			March 2025

			37,719

			37,719

			C$
			15.12

			August 2027 - Dec 2028

			43,031

			43,031

			$
			22.12

			Feb 2030

			51,006

			51,006

			$
			52.08 - 56.49

			September 2030 - Oct 2030

			81,041

			81,041

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			58,753

			57,304

			$
			25.97

			March 2025 - Feb 2032

			111,116

			70,025

			$
			4.10 - 10.01

			March 2025 - Oct 2033

			383,040

			340,500

The options exercisable at December 31, 2024 had a weighted average exercise price of $27.01 and no intrinsic value and a weighted average remaining life of 74 months. There were 42,540 options at December 31, 2024 that had not vested with a weighted average exercise price of $7.83 and no intrinsic value and a weighted average remaining life of 101 months.

The fair value of options granted during the three months ended December 31 2023 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Three Month Ended 

			December 31,2023

			Risk free interest rate

			4.92
			%

			Expected life

			5 years

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

The Company recorded $0.1 million and $0.2 million of share-based compensation expenses for the three months ended December 31, 2024 and 2023, respectively.

13

As of December 31, 2024, the Company had approximately $0.1 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of